Overview
CJC-1295 (No DAC) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) that does not incorporate a Drug Affinity Complex (DAC). In laboratory research settings, this results in a shorter persistence profile compared to DAC-modified variants, allowing investigation of transient receptor engagement and pulsatile signaling behavior.
This compound is supplied strictly for laboratory and investigational research purposes.
Compound Breakdown
Without DAC modification, CJC-1295 (No DAC) is cleared more rapidly in preclinical models, making it suitable for studying:
Short-duration GHRH receptor activation
Transient growth hormone signaling patterns
Temporal response characteristics following brief exposure
Comparative signaling kinetics versus long-acting analogs
This profile allows researchers to examine signaling dynamics without prolonged receptor occupancy.
Research Context
Research investigations involving CJC-1295 (No DAC) commonly explore:
Pulsatile endocrine signaling frameworks
Short-term growth hormone pathway activation
Comparative studies against DAC-modified GHRH analogs
Experimental models requiring controlled, time-limited signaling exposure
These investigations are limited to controlled laboratory environments and do not imply clinical or therapeutic outcomes.
Related Categories
CJC-1295 (No DAC) is frequently compared with CJC-1295 (DAC) Peptide and is commonly paired with complementary compounds such as Ipamorelin Peptide in growth hormone–related research.
